Suanfarma Suanfarma

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Philip Morris International","sponsor":"Philip Morris International","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Philip Morris International Acquires Inhaled Drug Specialist OtiTopic","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Undisclosed","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"August 2021","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed"},{"orgOrder":0,"company":"Philip Morris International","sponsor":"Fertin Pharma AS","pharmaFlowCategory":"D","amount":"$820.0 million","upfrontCash":"Undisclosed","newsHeadline":"Philip Morris International Announces Closing of Fertin Pharma Acquisition; Advances PMI\u2019s Goal of Becoming a Majority Smoke-Free Business by 2025 and Creates Growth Opportunities Beyond Nicotine","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed"},{"orgOrder":0,"company":"Philip Morris International","sponsor":"Fertin Pharma AS","pharmaFlowCategory":"D","amount":"$820.0 million","upfrontCash":"Undisclosed","newsHeadline":"Philip Morris International Announces Agreement to Acquire Fertin Pharma","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"July 2021","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Philip Morris International

    Menu

    Philip Morris International

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Philip Morris International

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Switzerland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Philip Morris International Announces Closing of Fertin Pharma Acquisition; Advances PMI’s Goal of Becoming a Majority Smoke-Free Business by 2025 and Creates Growth Oppo...

              Details:

              Through the acquisition, PMI will build its overall platform of R&D and manufacturing expertise in nicotine and beyond nicotine product areas through the addition of Fertin’s strong capabilities and skilled workforce.

              Lead Product(s): Nicotine

              Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Small molecule

              Recipient: Fertin Pharma AS

              Deal Size: $820.0 million Upfront Cash: Undisclosed

              Deal Type: Acquisition September 15, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Philip Morris International

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Switzerland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Philip Morris International Acquires Inhaled Drug Specialist OtiTopic

              Details:

              OtiTopic develops the Asprihale patented dry powder inhalation ASA treatment to treat acute myocardial infarction as a self-administered aerosol. The company expects to move from clinical trials of Asprihale to filing for FDA approval at some point in 2022.

              Lead Product(s): Aspirin

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Asprihale

              Highest Development Status: Undisclosed Product Type: Small molecule

              Recipient: OtiTopic

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Acquisition August 09, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Philip Morris International

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Switzerland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Philip Morris International Announces Agreement to Acquire Fertin Pharma

              Details:

              Through the acquisition, PMI will build its overall platform of R&D and manufacturing expertise in nicotine and beyond nicotine product areas through the addition of Fertin’s strong capabilities and skilled workforce.

              Lead Product(s): Nicotine

              Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Small molecule

              Recipient: Fertin Pharma AS

              Deal Size: $820.0 million Upfront Cash: Undisclosed

              Deal Type: Acquisition July 01, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Inke S.A: APIs manufacturing plant.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY